Affimed Therapeutics AG - The discovery and development of next generation antibodies for the treatment of cancer and other diseases with unmet medical need.

Press Room | Press Releases

05-06-2008	Affimed appoints Chief Business Officer
13-05-2008	Affimed validates antibody target for cancer metastasis
04-02-2008	Affimed Increases Series B Financing in Second B Financing in Second Closing to Euro 30 Million (USD 45 Million)
01-01-2008	Genetic engineering & biotechnical News Expanding Antibody Therapeutic Options Affimed Uses Multiple Libraries and Formats to Produce a Myriad of Drug Choices
04-04-2007	Affimed Closes € 25 M (US $ 32 M) Series B financing
04-12-2006	Affimed's fully human anti thrombosis antibody shows in vivo efficacy with reduced side effects
24-11-2006	Affimed obtains victory in challenge to key naive IgM-based antibody libraries patent
26-09-2006	Xoma and Affimed sign antibody cross-license and collaboration agreement
10-04-2006	InNexus Biotechnology and Affimed Therapeutics AG to Collaborate
18-01-2006	Affimed Therapeutics AG appoints Dr. Miroslav Ravic as Chief Medical Officer
15-07-2005	Affimed Therapeutics AG successfully completes series C financing round to support development of two cancer products
18-03-2005	Affimed AG complements management team
04-11-2004	Affimed Therapeutics and Biopharma Unit of Syngenta Enter Into Agreement to Co-develop TandAbs
01-10-2004	Affimed wins Aventis Behring Manager Rolf H. Günther as new Chief Executive Officer
12-08-2003	Affimed and Dyax Cross-License Antibody Technologies